Document Detail


New treatment options for acute coronary syndromes.
MedLine Citation:
PMID:  17203988     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Complications from atherosclerotic coronary artery disease are the principal cause of death worldwide. Many therapeutic strategies have been developed to reduce the burden of this disease. Systemic antithrombotic therapy, typically with unfractionated heparin, has long been a mainstay in the management of acute coronary syndromes (ACS) despite several limitations, including intravenous administration and unpredictable pharmacokinetics necessitating frequent monitoring. In recent years, newer agents without these limitations have been developed and evaluated in clinical trials. This review focuses on novel antithrombotic therapies for ACS, particularly fondaparinux sodium, a synthetic inhibitor of clotting factor Xa.
Authors:
Charles L Campbell
Related Documents :
10577408 - New-generation anticoagulants: the low molecular weight heparins.
15530128 - Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antipla...
19416088 - Pharmacological and clinical profile of bivalirudin in the treatment of patients with a...
18217148 - Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascula...
10577408 - New-generation anticoagulants: the low molecular weight heparins.
3621278 - Methodology for clinical trials with antiarrhythmic drugs to prevent cardiac death: us ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The American journal of managed care     Volume:  12     ISSN:  1088-0224     ISO Abbreviation:  Am J Manag Care     Publication Date:  2006 Dec 
Date Detail:
Created Date:  2007-01-05     Completed Date:  2007-04-16     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9613960     Medline TA:  Am J Manag Care     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S435-43     Citation Subset:  H    
Affiliation:
University of Kentucky, Gill Heart Institute, 900 S Limestone St, 326 Charles T. Wethington Bldg, Lexington, KY 40536-0200, USA. clcampbell@uky.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Coronary Artery Disease / drug therapy*
Fibrinolytic Agents / therapeutic use*
Humans
United States
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Burden of disease: medical and economic impact of acute coronary syndromes.
Next Document:  Easing the economic burden of acute coronary syndromes: cost-effectiveness of emerging therapies.